Pub Date : 2026-01-15Epub Date: 2025-11-06DOI: 10.1016/j.xhgg.2025.100543
Rose M Doss, Sara A Wirth, Jonathan W Pitsch, Caroline M Dias, Andrea L Gropman, Martin W Breuss
Homozygous loss-of-function mutations in LNPK, the gene encoding the endoplasmic reticulum-associated protein lunapark, have previously been linked to an autosomal recessive neurodevelopmental syndrome. Here, we describe an individual harboring compound heterozygous predicted splice site mutations with an overall matching phenotype. In cultured fibroblasts, these mutations result in a dearth of transcript and severe loss of protein, thereby establishing their likely pathogenicity. The underlying reduction in gene expression is due to the activation of the nonsense-mediated decay (NMD) pathway as a consequence of exon skipping rather than intron retention, leading to aberrant transcripts. We further demonstrate that cells from the affected individual and her mother exhibit a significant increase in transcript compared with a control cell line when treated with an inhibitor of NMD, suggesting potential genetic compensation. Together, this report describes disease-causing variants in LNPK and reveals their impact on transcription and mRNA stability.
{"title":"Exon-skipping due to bi-allelic splice site mutations in the neurodevelopmental disease gene LNPK.","authors":"Rose M Doss, Sara A Wirth, Jonathan W Pitsch, Caroline M Dias, Andrea L Gropman, Martin W Breuss","doi":"10.1016/j.xhgg.2025.100543","DOIUrl":"10.1016/j.xhgg.2025.100543","url":null,"abstract":"<p><p>Homozygous loss-of-function mutations in LNPK, the gene encoding the endoplasmic reticulum-associated protein lunapark, have previously been linked to an autosomal recessive neurodevelopmental syndrome. Here, we describe an individual harboring compound heterozygous predicted splice site mutations with an overall matching phenotype. In cultured fibroblasts, these mutations result in a dearth of transcript and severe loss of protein, thereby establishing their likely pathogenicity. The underlying reduction in gene expression is due to the activation of the nonsense-mediated decay (NMD) pathway as a consequence of exon skipping rather than intron retention, leading to aberrant transcripts. We further demonstrate that cells from the affected individual and her mother exhibit a significant increase in transcript compared with a control cell line when treated with an inhibitor of NMD, suggesting potential genetic compensation. Together, this report describes disease-causing variants in LNPK and reveals their impact on transcription and mRNA stability.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100543"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12670907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-09-02DOI: 10.1016/j.xhgg.2025.100500
Daniel Levey, Marco Galimberti, Joseph Deak, Priya Gupta, Stefany L L Empke, Keyrun Adhikari, Kelly Harrington, Rachel Quaden, J J Michael Gaziano, Murray B Stein, Joel Gelernter
Antidepressants are among the most-prescribed drugs worldwide, and selective serotonin reuptake inhibitors (SSRIs) are among the most prescribed antidepressants, most commonly used for major depression. We sought to increase our understanding of the biological relationships between SSRI use and a range of psychiatric traits by conducting a genome-wide association study (GWAS) in two large datasets, the UK Biobank (UKB) and the US Million Veteran Program (MVP). GWAS was conducted across 22 autosomes and the X chromosome in 777,952 individuals of European ancestry (191,800 SSRI users, 586,152 control individuals) and 112,526 individuals of African ancestry (53,499 SSRI users, 59,027 control individuals). We identified 40 genome-wide significant (GWS) loci, including two on the X chromosome. Using linkage disequilibrium score regression, we detected strong genetic correlations between MVP and the independent UKB cohort for specific SSRIs (fluoxetine rg = 0.82, citalopram rG = 0.89) as well as with headaches (rG = 0.80), major depressive disorder (MDD; rG = 0.77), and spondylosis (rG = 0.84), suggesting stability in trait definition across cohorts. To evaluate differences in genomic variance captured by SSRI use vs. MDD, we performed a comparative rG analysis and found significant differences, most notably for educational attainment (SSRI rG = -0.38, MDD rG = -0.26), cognitive performance (SSRI rG = -0.31, MDD rG = -0.15), and depression (SSRI rG = 0.80, MDD rG = 0.97). In MVP, SSRI use showed greater locus discovery than MDD (28 vs. 17 loci); comparison to a prior GWAS of anxiety symptoms identified only five loci. SSRI use is likely a partial proxy for MDD, while also reflecting distinct features relevant to related disorders such as anxiety.
{"title":"Genetics of SSRI antidepressant use and relationship to psychiatric and medical traits.","authors":"Daniel Levey, Marco Galimberti, Joseph Deak, Priya Gupta, Stefany L L Empke, Keyrun Adhikari, Kelly Harrington, Rachel Quaden, J J Michael Gaziano, Murray B Stein, Joel Gelernter","doi":"10.1016/j.xhgg.2025.100500","DOIUrl":"10.1016/j.xhgg.2025.100500","url":null,"abstract":"<p><p>Antidepressants are among the most-prescribed drugs worldwide, and selective serotonin reuptake inhibitors (SSRIs) are among the most prescribed antidepressants, most commonly used for major depression. We sought to increase our understanding of the biological relationships between SSRI use and a range of psychiatric traits by conducting a genome-wide association study (GWAS) in two large datasets, the UK Biobank (UKB) and the US Million Veteran Program (MVP). GWAS was conducted across 22 autosomes and the X chromosome in 777,952 individuals of European ancestry (191,800 SSRI users, 586,152 control individuals) and 112,526 individuals of African ancestry (53,499 SSRI users, 59,027 control individuals). We identified 40 genome-wide significant (GWS) loci, including two on the X chromosome. Using linkage disequilibrium score regression, we detected strong genetic correlations between MVP and the independent UKB cohort for specific SSRIs (fluoxetine rg = 0.82, citalopram rG = 0.89) as well as with headaches (rG = 0.80), major depressive disorder (MDD; rG = 0.77), and spondylosis (rG = 0.84), suggesting stability in trait definition across cohorts. To evaluate differences in genomic variance captured by SSRI use vs. MDD, we performed a comparative rG analysis and found significant differences, most notably for educational attainment (SSRI rG = -0.38, MDD rG = -0.26), cognitive performance (SSRI rG = -0.31, MDD rG = -0.15), and depression (SSRI rG = 0.80, MDD rG = 0.97). In MVP, SSRI use showed greater locus discovery than MDD (28 vs. 17 loci); comparison to a prior GWAS of anxiety symptoms identified only five loci. SSRI use is likely a partial proxy for MDD, while also reflecting distinct features relevant to related disorders such as anxiety.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100500"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eye diseases, including cataracts, glaucoma, diabetes retinopathy, and age-related macular degeneration, are major global health challenges and leading causes of blindness. This study leveraged genome-wide association studies (GWASs) involving over 100,000 individuals, integrating data from the Taiwan Biobank and National Health Insurance Research Database, to identify genetic loci associated with disease onset. Our findings suggest that these conditions are influenced by multifactorial etiologies, as pleiotropic loci including rs10811660, rs4710941, rs2283228, and rs7646518 were identified, linking ocular diseases to metabolic conditions. Notably, a strong genetic correlation was observed between cataract and depression. Mendelian randomization analysis further demonstrated a causal effect of depression on cataract risk, implicating shared biological pathways, particularly oxytocin signaling, in disease pathophysiology. This finding revealed a functional genetic variant near the OXTR gene, highlighting its potential as a causal candidate for genetic diagnosis in precision health. By bridging the gap between genetic discovery and clinical application, this research offers critical insights into shared genetic mechanisms across diverse health domains, paving the way for innovative diagnostic and therapeutic strategies.
{"title":"Genome-wide association study reveals genetic mechanisms underlie eye disorders and comorbidities.","authors":"Chia-Ni Hsiung, Wen-Cheng Chou, Chih-Hsiung Hsu, Linyi Chen","doi":"10.1016/j.xhgg.2025.100520","DOIUrl":"10.1016/j.xhgg.2025.100520","url":null,"abstract":"<p><p>Eye diseases, including cataracts, glaucoma, diabetes retinopathy, and age-related macular degeneration, are major global health challenges and leading causes of blindness. This study leveraged genome-wide association studies (GWASs) involving over 100,000 individuals, integrating data from the Taiwan Biobank and National Health Insurance Research Database, to identify genetic loci associated with disease onset. Our findings suggest that these conditions are influenced by multifactorial etiologies, as pleiotropic loci including rs10811660, rs4710941, rs2283228, and rs7646518 were identified, linking ocular diseases to metabolic conditions. Notably, a strong genetic correlation was observed between cataract and depression. Mendelian randomization analysis further demonstrated a causal effect of depression on cataract risk, implicating shared biological pathways, particularly oxytocin signaling, in disease pathophysiology. This finding revealed a functional genetic variant near the OXTR gene, highlighting its potential as a causal candidate for genetic diagnosis in precision health. By bridging the gap between genetic discovery and clinical application, this research offers critical insights into shared genetic mechanisms across diverse health domains, paving the way for innovative diagnostic and therapeutic strategies.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100520"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12524058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-10-25DOI: 10.1016/j.xhgg.2025.100537
Joery den Hoed, Fleur Semmekrot, Jolijn Verseput, Alexander J M Dingemans, Dick Schijven, Clyde Francks, Yuri A Zarate, Simon E Fisher
SATB2-associated syndrome is an autosomal dominant neurodevelopmental syndrome caused by genetic alterations in the transcription factor SATB2. The associated phenotype is variable, and genotype-phenotype correlation studies have not yet been able to explain differences in severity and symptoms across affected individuals. While haploinsufficiency is the most often described disease mechanism, with the majority of variants consisting of whole- or partial-gene deletions and protein truncating variants with predicted loss of function, approximately one-third of affected individuals carry a SATB2 missense variant with an unknown effect. In this study, we sought to functionally characterize these missense variants to uncover associated pathogenic mechanisms. We combined a set of human cell-based experiments to screen 31 etiological SATB2 missense variants for effects on nuclear localization, global chromatin binding, and transcriptional activity. Our data indicate partial loss-of-function effects for most of the studied missense variants but identify at least eight variants with increased SATB2 function showing a combination (or subset) of features that include stronger co-localization with DNA, decreased nuclear protein mobility suggesting increased overall chromatin binding, and maintained or increased transcriptional activity. These results demonstrate that phenotypes associated with variants in SATB2 may have distinct underlying disease mechanisms, and the data could provide a resource for future studies investigating disease variability and potential therapies for this condition.
{"title":"Functional characterization of pathogenic SATB2 missense variants identifies distinct effects on chromatin binding and transcriptional activity.","authors":"Joery den Hoed, Fleur Semmekrot, Jolijn Verseput, Alexander J M Dingemans, Dick Schijven, Clyde Francks, Yuri A Zarate, Simon E Fisher","doi":"10.1016/j.xhgg.2025.100537","DOIUrl":"10.1016/j.xhgg.2025.100537","url":null,"abstract":"<p><p>SATB2-associated syndrome is an autosomal dominant neurodevelopmental syndrome caused by genetic alterations in the transcription factor SATB2. The associated phenotype is variable, and genotype-phenotype correlation studies have not yet been able to explain differences in severity and symptoms across affected individuals. While haploinsufficiency is the most often described disease mechanism, with the majority of variants consisting of whole- or partial-gene deletions and protein truncating variants with predicted loss of function, approximately one-third of affected individuals carry a SATB2 missense variant with an unknown effect. In this study, we sought to functionally characterize these missense variants to uncover associated pathogenic mechanisms. We combined a set of human cell-based experiments to screen 31 etiological SATB2 missense variants for effects on nuclear localization, global chromatin binding, and transcriptional activity. Our data indicate partial loss-of-function effects for most of the studied missense variants but identify at least eight variants with increased SATB2 function showing a combination (or subset) of features that include stronger co-localization with DNA, decreased nuclear protein mobility suggesting increased overall chromatin binding, and maintained or increased transcriptional activity. These results demonstrate that phenotypes associated with variants in SATB2 may have distinct underlying disease mechanisms, and the data could provide a resource for future studies investigating disease variability and potential therapies for this condition.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100537"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12639615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145373178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-10-09DOI: 10.1016/j.xhgg.2025.100527
Zeta Chow, Jinpeng Liu, Daheng He, Chi Wang, Tong Gan, Akila Mansour, Nuha Shaker, Caroline Dravillas, Rebecca Hoyd, Eric Durbin, Dana Napier, Tianyan Gao, Kurt Schaberg, Lyen Huang, Neli Ulrich, Erin Siegel, Stephen Edge, Linda Cook, Bodour Salhia, Michelle Churchman, Jill Kolesar, Daniel Spakowicz, B Mark Evers, Therese Bocklage
We investigated colon cancer genomics and microenvironmental features in the Appalachian Kentucky population, a group with the highest incidence of colon cancer in the United States. We assessed two inter-related risk factors for colon cancer (obesity and abnormal gut bacterial microbiome) and their genetic associations within this population. To evaluate potential unique characteristics of the high-incidence cohort, we compared 99 propensity-matched colon cancer tumors from Appalachian Kentucky patients to 95 non-Appalachian patient tumors to evaluate driver mutations, differentially expressed genes (DEGs), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, Catalogue of Somatic Mutations in Cancer (COSMIC) mutational signatures, immune cell populations, and microbiomes in an obesity context. Our comparison identified significant population-specific DEGs and differences in COSMIC signature frequencies, KEGG pathway regulation, pro-carcinogenic immune cell features, microbiome species, and obesity-associated inflammatory and metabolic responses between the cohorts. The findings offer generalizable implications deriving from Appalachian Kentuckians while highlighting the critical importance of population-based studies in colon cancer research.
{"title":"Colon cancer in Appalachian Kentucky: Unique genetic, microbiome and obesity findings in a cohort comparison.","authors":"Zeta Chow, Jinpeng Liu, Daheng He, Chi Wang, Tong Gan, Akila Mansour, Nuha Shaker, Caroline Dravillas, Rebecca Hoyd, Eric Durbin, Dana Napier, Tianyan Gao, Kurt Schaberg, Lyen Huang, Neli Ulrich, Erin Siegel, Stephen Edge, Linda Cook, Bodour Salhia, Michelle Churchman, Jill Kolesar, Daniel Spakowicz, B Mark Evers, Therese Bocklage","doi":"10.1016/j.xhgg.2025.100527","DOIUrl":"10.1016/j.xhgg.2025.100527","url":null,"abstract":"<p><p>We investigated colon cancer genomics and microenvironmental features in the Appalachian Kentucky population, a group with the highest incidence of colon cancer in the United States. We assessed two inter-related risk factors for colon cancer (obesity and abnormal gut bacterial microbiome) and their genetic associations within this population. To evaluate potential unique characteristics of the high-incidence cohort, we compared 99 propensity-matched colon cancer tumors from Appalachian Kentucky patients to 95 non-Appalachian patient tumors to evaluate driver mutations, differentially expressed genes (DEGs), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, Catalogue of Somatic Mutations in Cancer (COSMIC) mutational signatures, immune cell populations, and microbiomes in an obesity context. Our comparison identified significant population-specific DEGs and differences in COSMIC signature frequencies, KEGG pathway regulation, pro-carcinogenic immune cell features, microbiome species, and obesity-associated inflammatory and metabolic responses between the cohorts. The findings offer generalizable implications deriving from Appalachian Kentuckians while highlighting the critical importance of population-based studies in colon cancer research.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100527"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12554973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-11-19DOI: 10.1016/j.xhgg.2025.100549
Ying Hao, Qian Geng, Xingping Li, Jingxin Yang, Yang Liu, Qingfa Huang, Yong Xu, Peining Li, Jiansheng Xie, Weiqing Wu, Bo Wu, Wenlan Liu
Chromosomal microarray analysis (CMA) detects pathogenic copy-number variants (pCNVs) and regions of homozygosity (ROHs) in prenatal genetic analysis. This study evaluates the clinical significance of ROH detection in prenatal settings. We reviewed 178 fetuses with ROH detected by CMA among 20,546 fetuses from 2015 to 2023. Clinical and laboratory results, including ultrasound anomalies, cell-free DNA (cfDNA) screening, karyotyping, exome sequencing (ES), and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), were analyzed. These 178 fetuses with ROH accounted for 0.87% of prenatal cases. Among them, 24.2% had positive cfDNA screening results, and 52.8% underwent follow-up ES, trio CMA, and MS-MLPA. Follow-up studies detected pathogenic homozygous variants within ROH in two fetuses and uniparental disomy (UPD)-related diseases in five fetuses. Our results and findings from the other five large prenatal case series from literature indicated that ROH detection in prenatal CMA has a baseline positive predictive value of 2.7% for autosomal-recessive disorders, 9.6% for UPD-related diseases, and 0.04% overall additive diagnostic yield. These findings support the use of ES and MS-MLPA for follow-up testing and provide guidance for genetic counseling in fetuses with ROH.
{"title":"Clinical significance of regions of homozygosity detection in prenatal chromosomal microarray analysis.","authors":"Ying Hao, Qian Geng, Xingping Li, Jingxin Yang, Yang Liu, Qingfa Huang, Yong Xu, Peining Li, Jiansheng Xie, Weiqing Wu, Bo Wu, Wenlan Liu","doi":"10.1016/j.xhgg.2025.100549","DOIUrl":"10.1016/j.xhgg.2025.100549","url":null,"abstract":"<p><p>Chromosomal microarray analysis (CMA) detects pathogenic copy-number variants (pCNVs) and regions of homozygosity (ROHs) in prenatal genetic analysis. This study evaluates the clinical significance of ROH detection in prenatal settings. We reviewed 178 fetuses with ROH detected by CMA among 20,546 fetuses from 2015 to 2023. Clinical and laboratory results, including ultrasound anomalies, cell-free DNA (cfDNA) screening, karyotyping, exome sequencing (ES), and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), were analyzed. These 178 fetuses with ROH accounted for 0.87% of prenatal cases. Among them, 24.2% had positive cfDNA screening results, and 52.8% underwent follow-up ES, trio CMA, and MS-MLPA. Follow-up studies detected pathogenic homozygous variants within ROH in two fetuses and uniparental disomy (UPD)-related diseases in five fetuses. Our results and findings from the other five large prenatal case series from literature indicated that ROH detection in prenatal CMA has a baseline positive predictive value of 2.7% for autosomal-recessive disorders, 9.6% for UPD-related diseases, and 0.04% overall additive diagnostic yield. These findings support the use of ES and MS-MLPA for follow-up testing and provide guidance for genetic counseling in fetuses with ROH.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100549"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-12-08DOI: 10.1016/j.xhgg.2025.100553
Rebecca M K Berns, Devika Dhamija, Daniella Coker, Chelsea L Robertson, Jingran Wen, R Ryanne Wu, Michael V Holmes, Noura S Abul-Husn
Depression is a frequent focus of interest in genetic testing. Despite the growing availability of polygenic risk scores (PRSs) for depression, little is known about the psychological impact of receiving them in real-world settings. To quantify the impact of receiving an at-risk depression PRS result on depression and anxiety symptoms, we conducted a longitudinal, prospective cohort study of 23andMe research participants. Eligible participants were US residents 18 years old and older who completed two surveys between October 19, 2022 and October 9, 2023 assessing depression and anxiety symptoms and who had an at-risk PRS for depression (odds ratio ≥1.5). We compared 361 individuals who viewed their result with 556 who did not. Primary outcomes were changes in depression (Patient Health Questionnaire-8) and anxiety (Depression Anxiety Stress Scale-21) symptom scores relative to baseline. We fitted linear regressions to model each outcome, adjusting for age, sex, ancestry, income, prior depression and/or anxiety, and baseline scores. Using an equivalence testing framework, the smallest effect size of interest was defined as Cohen's d = ±0.5. Score changes from baseline to follow-up were statistically equivalent for individuals who viewed results and those who did not (adjusted between-group differences in score changes: depression, -0.17 points [90% confidence interval {CI} -0.59 to 0.24]; anxiety, -0.092 points [90% CI -0.35 to 0.17]; all p < 0.001). Results were consistent in substrata with or without prior depression or anxiety. We conclude that among genetically at-risk individuals, exposure to a depression PRS result was well tolerated in a real-world setting.
抑郁症是基因检测中经常关注的焦点。尽管抑郁症的多基因风险评分(PRS)越来越多,但人们对在现实环境中接受这些评分的心理影响知之甚少。为了量化接受高危抑郁PRS结果对抑郁和焦虑症状的影响,我们对23andMe研究参与者进行了纵向前瞻性队列研究。符合条件的参与者为≥18岁的美国居民,他们在2022年10月19日至2023年10月9日期间完成了两项评估抑郁和焦虑症状的调查,并且患有抑郁症的危险PRS(优势比≥1.5)。我们比较了361名看过结果的人和556名没有看过结果的人。主要结局是抑郁(患者健康问卷-8)和焦虑(抑郁焦虑压力量表-21)症状评分相对于基线的变化。我们拟合线性回归对每个结果建模,调整年龄、性别、血统、收入、既往抑郁和/或焦虑以及基线得分。使用等效检验框架,最小效应量定义为Cohen’s d =±0.5。观察结果和未观察结果的个体从基线到随访的评分变化在统计学上是相等的(调整后的组间评分变化差异:抑郁,-0.17分[90% CI -0.59-0.24];焦虑,-0.092分[90% CI -0.35-0.17];均p < 0.001)。结果与既往有无抑郁或焦虑的受试者一致。我们得出的结论是,在基因上有风险的个体中,暴露于抑郁PRS结果在现实环境中是良好耐受的。
{"title":"Viewing direct-to-consumer genetic test results for depression risk is psychologically well tolerated: Evidence from a longitudinal equivalence study.","authors":"Rebecca M K Berns, Devika Dhamija, Daniella Coker, Chelsea L Robertson, Jingran Wen, R Ryanne Wu, Michael V Holmes, Noura S Abul-Husn","doi":"10.1016/j.xhgg.2025.100553","DOIUrl":"10.1016/j.xhgg.2025.100553","url":null,"abstract":"<p><p>Depression is a frequent focus of interest in genetic testing. Despite the growing availability of polygenic risk scores (PRSs) for depression, little is known about the psychological impact of receiving them in real-world settings. To quantify the impact of receiving an at-risk depression PRS result on depression and anxiety symptoms, we conducted a longitudinal, prospective cohort study of 23andMe research participants. Eligible participants were US residents 18 years old and older who completed two surveys between October 19, 2022 and October 9, 2023 assessing depression and anxiety symptoms and who had an at-risk PRS for depression (odds ratio ≥1.5). We compared 361 individuals who viewed their result with 556 who did not. Primary outcomes were changes in depression (Patient Health Questionnaire-8) and anxiety (Depression Anxiety Stress Scale-21) symptom scores relative to baseline. We fitted linear regressions to model each outcome, adjusting for age, sex, ancestry, income, prior depression and/or anxiety, and baseline scores. Using an equivalence testing framework, the smallest effect size of interest was defined as Cohen's d = ±0.5. Score changes from baseline to follow-up were statistically equivalent for individuals who viewed results and those who did not (adjusted between-group differences in score changes: depression, -0.17 points [90% confidence interval {CI} -0.59 to 0.24]; anxiety, -0.092 points [90% CI -0.35 to 0.17]; all p < 0.001). Results were consistent in substrata with or without prior depression or anxiety. We conclude that among genetically at-risk individuals, exposure to a depression PRS result was well tolerated in a real-world setting.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100553"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-09-29DOI: 10.1016/j.xhgg.2025.100525
Brianna L DiSanza, Giulia S Porcari, Livia Sertori Finoti, Leonardo Ramos-Rodriguez, Devin M Burris, Justin A McDonough, Gang Ning, Grace Fagan, Guy T Helman, Erin Weiss, Ryan J Taft, Amy Pizzino, Matthew T Whitehead, Amy Waldman, Cas Simons, Xilma Ortiz-Gonzalez, William C Skarnes, Adeline Vanderver, Elizabeth J Bhoj, Rebecca C Ahrens-Nicklas
Branched-chain amino acid transaminase-1 (BCAT1) initiates the catabolism of branched-chain amino acids (BCAAs), which are essential for neurologic function. However, the role of BCAT1 in neurodevelopment is largely unknown. Here, we identify compound heterozygous BCAT1 variants in a patient with a severe progressive neurodevelopmental syndrome. To investigate the functional consequences, we established patient variant (BCAT1: c.792T>A p.Phe264Leu; c.1042G>A p.Glu348Lys) and BCAT1 knockout hiPSC models. Both disease models show profound defects in cortical neuron differentiation and neurite outgrowth. Furthermore, metabolic analysis revealed evidence of mitochondrial dysfunction associated with increased levels of tricarboxylic acid (TCA) cycle intermediates, glutamate, and glutamine. This increase is linked to altered oxygen consumption rates, superoxide production, and upregulation of UCP2 in BCAT1 disease neurons, suggesting a downstream impact on electron transport chain homeostasis. These findings establish a regulatory role for BCAT1 in mitochondrial function and further define a role for genomic variants in BCAT1 in neurometabolic disorders.
{"title":"Bi-allelic variants in BCAT1 impair mitochondrial function and are associated with a candidate neurometabolic disorder.","authors":"Brianna L DiSanza, Giulia S Porcari, Livia Sertori Finoti, Leonardo Ramos-Rodriguez, Devin M Burris, Justin A McDonough, Gang Ning, Grace Fagan, Guy T Helman, Erin Weiss, Ryan J Taft, Amy Pizzino, Matthew T Whitehead, Amy Waldman, Cas Simons, Xilma Ortiz-Gonzalez, William C Skarnes, Adeline Vanderver, Elizabeth J Bhoj, Rebecca C Ahrens-Nicklas","doi":"10.1016/j.xhgg.2025.100525","DOIUrl":"10.1016/j.xhgg.2025.100525","url":null,"abstract":"<p><p>Branched-chain amino acid transaminase-1 (BCAT1) initiates the catabolism of branched-chain amino acids (BCAAs), which are essential for neurologic function. However, the role of BCAT1 in neurodevelopment is largely unknown. Here, we identify compound heterozygous BCAT1 variants in a patient with a severe progressive neurodevelopmental syndrome. To investigate the functional consequences, we established patient variant (BCAT1: c.792T>A p.Phe264Leu; c.1042G>A p.Glu348Lys) and BCAT1 knockout hiPSC models. Both disease models show profound defects in cortical neuron differentiation and neurite outgrowth. Furthermore, metabolic analysis revealed evidence of mitochondrial dysfunction associated with increased levels of tricarboxylic acid (TCA) cycle intermediates, glutamate, and glutamine. This increase is linked to altered oxygen consumption rates, superoxide production, and upregulation of UCP2 in BCAT1 disease neurons, suggesting a downstream impact on electron transport chain homeostasis. These findings establish a regulatory role for BCAT1 in mitochondrial function and further define a role for genomic variants in BCAT1 in neurometabolic disorders.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100525"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12670911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-09-27DOI: 10.1016/j.xhgg.2025.100524
Carissa A Sherman, Nanibaa' A Garrison, Katrina G Claw
The Navajo Nation is reevaluating a moratorium on genetic research that was authorized in 2002. While the moratorium was instituted due to cultural concerns and the lack of a Navajo genetic research policy, there remains limited empirical work assessing the perspectives of Diné (Navajo) people and other interest holders regarding genetic research. To address this gap, this study examines the perspectives of research project leaders with protocols approved by the Navajo Nation Human Research Review Board (NNHRRB) as this group is aware of research expectations and cultural considerations. An online survey was designed to gauge researchers' interest in adding a genetic component to their research if the moratorium were lifted, while also examining potential benefits, risks, and ethical considerations. Survey participants (n = 36) included 27% Diné researchers and 73% non-Diné researchers, and 50% of researchers (n = 18) had collected human biospecimens in their research (e.g., blood, tissue). Our results indicate that, if the moratorium on genetic research ended, 42% of researchers (n = 15) would be unsure about adding a genetic component to their projects, while 31% (n = 11) of researchers were interested. Participants were asked to rank ethical considerations related to five broad topics: community engagement; dissemination of results and data; privacy and rights; health, safety, and equity; and discrimination and mistrust. Participants ranked "ensure that no research participants are harmed" and "give presentations to the community" as very important, whereas "sharing data with other researchers" was of low importance. We provide valuable perspectives to guide potential genetic policy development for the Navajo Nation.
{"title":"Researcher attitudes toward hypothetical genetic research with Navajo people: Results from an online survey.","authors":"Carissa A Sherman, Nanibaa' A Garrison, Katrina G Claw","doi":"10.1016/j.xhgg.2025.100524","DOIUrl":"10.1016/j.xhgg.2025.100524","url":null,"abstract":"<p><p>The Navajo Nation is reevaluating a moratorium on genetic research that was authorized in 2002. While the moratorium was instituted due to cultural concerns and the lack of a Navajo genetic research policy, there remains limited empirical work assessing the perspectives of Diné (Navajo) people and other interest holders regarding genetic research. To address this gap, this study examines the perspectives of research project leaders with protocols approved by the Navajo Nation Human Research Review Board (NNHRRB) as this group is aware of research expectations and cultural considerations. An online survey was designed to gauge researchers' interest in adding a genetic component to their research if the moratorium were lifted, while also examining potential benefits, risks, and ethical considerations. Survey participants (n = 36) included 27% Diné researchers and 73% non-Diné researchers, and 50% of researchers (n = 18) had collected human biospecimens in their research (e.g., blood, tissue). Our results indicate that, if the moratorium on genetic research ended, 42% of researchers (n = 15) would be unsure about adding a genetic component to their projects, while 31% (n = 11) of researchers were interested. Participants were asked to rank ethical considerations related to five broad topics: community engagement; dissemination of results and data; privacy and rights; health, safety, and equity; and discrimination and mistrust. Participants ranked \"ensure that no research participants are harmed\" and \"give presentations to the community\" as very important, whereas \"sharing data with other researchers\" was of low importance. We provide valuable perspectives to guide potential genetic policy development for the Navajo Nation.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100524"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12554029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-15Epub Date: 2025-10-08DOI: 10.1016/j.xhgg.2025.100529
Daniel E Cruz, Shuliang Deng, Usman A Tahir, Zsu-Zsu Chen, Mark D Benson, Bjoernar Tuftin, Jiawen Chen, Laurie Farrell, Dongxiao Shen, Mariah Meyer, Ethan Lange, Yan Gao, Michael E Hall, Russell P Tracy, Stephen S Rich, Kent Taylor, Ani Manichaikul, Jerome I Rotter, Tamar Sofer, James G Wilson, Robert E Gerszten, Laura M Raffield
Protein profiling and genetic findings can be integrated to define the genetic architecture of the circulating proteome in chronic diseases. Most self-identified African American (AA) individuals have both African and European genetic ancestry. Admixture mapping can detect genomic association regions in which causal variants exist with substantial differences in allele frequency or effect sizes between genetic ancestries. We performed admixture mapping of the circulating proteome in 1,989 participants from the Jackson Heart Study (JHS), investigating the relation of local African ancestry within genomic regions with levels of circulating proteins. We conditioned protein-local ancestry association models on variants previously found to be associated with those proteins in genome-wide association studies (GWASs). We replicated findings in 196 AA participants from the Multi-Ethnic Study of Atherosclerosis (MESA). 62 proteins were associated with local African ancestry. 21 of 62 remained statistically significant after conditioning on protein-associated variants observed in previous GWASs. 48 of 54 available protein-local ancestry associations were replicated in the MESA. Proteins associated with local African ancestry included chemokines, factors associated with vascular biology and inflammation, and other biologically interesting proteins. Admixture associations unexplained by previously reported protein-associated variants in conditional analysis suggest the existence of causal variants missed by standard GWAS techniques.
{"title":"Admixture-mapping analysis reveals genetic determinants of the human plasma proteome.","authors":"Daniel E Cruz, Shuliang Deng, Usman A Tahir, Zsu-Zsu Chen, Mark D Benson, Bjoernar Tuftin, Jiawen Chen, Laurie Farrell, Dongxiao Shen, Mariah Meyer, Ethan Lange, Yan Gao, Michael E Hall, Russell P Tracy, Stephen S Rich, Kent Taylor, Ani Manichaikul, Jerome I Rotter, Tamar Sofer, James G Wilson, Robert E Gerszten, Laura M Raffield","doi":"10.1016/j.xhgg.2025.100529","DOIUrl":"10.1016/j.xhgg.2025.100529","url":null,"abstract":"<p><p>Protein profiling and genetic findings can be integrated to define the genetic architecture of the circulating proteome in chronic diseases. Most self-identified African American (AA) individuals have both African and European genetic ancestry. Admixture mapping can detect genomic association regions in which causal variants exist with substantial differences in allele frequency or effect sizes between genetic ancestries. We performed admixture mapping of the circulating proteome in 1,989 participants from the Jackson Heart Study (JHS), investigating the relation of local African ancestry within genomic regions with levels of circulating proteins. We conditioned protein-local ancestry association models on variants previously found to be associated with those proteins in genome-wide association studies (GWASs). We replicated findings in 196 AA participants from the Multi-Ethnic Study of Atherosclerosis (MESA). 62 proteins were associated with local African ancestry. 21 of 62 remained statistically significant after conditioning on protein-associated variants observed in previous GWASs. 48 of 54 available protein-local ancestry associations were replicated in the MESA. Proteins associated with local African ancestry included chemokines, factors associated with vascular biology and inflammation, and other biologically interesting proteins. Admixture associations unexplained by previously reported protein-associated variants in conditional analysis suggest the existence of causal variants missed by standard GWAS techniques.</p>","PeriodicalId":34530,"journal":{"name":"HGG Advances","volume":" ","pages":"100529"},"PeriodicalIF":3.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12657719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}